{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:13:48Z","timestamp":1779002028372,"version":"3.51.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Heart Failure"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Heart failure (HF) is a disease commonly associated with coronary artery disease. Most risk models for HF development have focused on patients with acute myocardial infarction. The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            In the 8290, Prevention of Events with Angiotensin-Converting Enzyme Inhibition patients without preexisting HF, new-onset HF hospitalizations, and fatal HF were assessed over a median follow-up of 4.8 years. Covariates were evaluated and maintained in the Cox regression multivariable model using backward selection if\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05. A risk score was developed and converted to an integer-based scoring system. Among the Prevention of Events with Angiotensin-Converting Enzyme Inhibition population (age, 64\ufffd8; female, 18%; prior myocardial infarction, 55%), there were 268 cases of fatal and nonfatal HF. Twelve characteristics were associated with increased risk of HF along with several baseline medications, including older age, history of hypertension, and diabetes. Randomization to trandolapril independently reduced the risk of HF. There was no interaction between trandolapril treatment and other risk factors for HF. The risk score (range, 0 to 21) demonstrated excellent discriminatory power (c-statistic 0.80). Risk of HF ranged from 1.75% in patients with a risk score of 0% to 33% in patients with risk score \u226516.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusion\u2014<\/jats:italic>\n            <\/jats:bold>\n            Among patients with stable coronary artery disease and preserved ejection fraction, traditional and newer factors were independently associated with increased risk of HF. Trandolopril decreased the risk of HF in these patients with preserved ejection fraction.\n          <\/jats:p>","DOI":"10.1161\/circheartfailure.108.820696","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:39:45Z","timestamp":1239755985000},"page":"209-216","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Predictors of Heart Failure in Patients With Stable Coronary Artery Disease"],"prefix":"10.1161","volume":"2","author":[{"given":"Eldrin F.","family":"Lewis","sequence":"first","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Jablonski","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline Murguia","family":"Rice","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Clemenza","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Zabalgoitia","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thao","family":"Huynh","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Cuddy","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Rouleau","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Division (E.F.L., S.D.S., E.B., M.A.P.), Brigham and Women\u2019s Hospital, Boston, Mass; Biostatistics Center (K.A.J., M.M.R.), George Washington University, Washington, DC and Rockville, Md; Mediterranean Institute for Transplantation and Advanced Specialized Therapies (F.C.), Palermo, Italy; Astra Zeneca (J.H.), Wilmington, Del; AMNCO Foundation (A.P.M.), Florence, Italy; Department of Medicine (M.Z.), University of Texas Health Science Center, San Antonio, Tex; Montreal..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.104.23.2855"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.048"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(79)90250-9"},{"key":"e_1_3_2_4_2","first-page":"23","volume":"8","year":"1987","unstructured":"Kannel WB Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J. 1987; 8 (suppl F): 23\u201326.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490120059029"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00108-4"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"40J","DOI":"10.1016\/S0002-9149(97)00838-2","volume":"80","year":"1997","unstructured":"Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol. 1997; 80: 40J\u201344J.","journal-title":"Am J Cardiol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_3_2_9_2","unstructured":"Heart Disease and Stroke Statistics\u20142005 Update. Dallas Tex: American Heart Association 2005."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.544031"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550030052033"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn062"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.12.018"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)01057-X"},{"key":"e_1_3_2_15_2","first-page":"821","volume":"342","year":"1993","unstructured":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342: 821\u2013828.","journal-title":"Lancet"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042739"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra054415"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(97)00043-6"},{"key":"e_1_3_2_21_2","unstructured":"Hosmer DW Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York NY: John Wiley & Sons; 1999."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.105.3.310"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1802"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053241"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.07.061"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530440037034"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000054165.93055.42"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl122"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041365"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.580506"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00608-7"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.592733"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000141726.01302.83"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.03.038"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00008"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2004.04.011"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.187930"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69201-5"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.05.018"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2006.10.012"}],"container-title":["Circulation: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCHEARTFAILURE.108.820696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T01:16:57Z","timestamp":1715563017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCHEARTFAILURE.108.820696"}},"subtitle":["A PEACE Study"],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1161\/CIRCHEARTFAILURE.108.820696"],"URL":"https:\/\/doi.org\/10.1161\/circheartfailure.108.820696","relation":{},"ISSN":["1941-3289","1941-3297"],"issn-type":[{"value":"1941-3289","type":"print"},{"value":"1941-3297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"2009-04-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}